June 18, 2025

Cracking the Code of Phages to Fight TB

How new structural insights captured in high-resolution images could fuel next-gen therapies for TB

The Analytical Scientist

June 17, 2025

FDA-Approved Sweetener Found in Vapes

New laboratory analysis found widespread use of neotame, a potent artificial sweetener, in most disposable e-cigarettes sold in the United States, including nicotine-free and nicotine-analogue products.

Conexiant

June 16, 2025

How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC?

Medicaid expansion was associated with a 2.8% increase in lung cancer surgeries performed and a 2.1% increase in surgeries completed within 90 days of diagnosis at high-volume hospitals.

The ASCO Post

June 16, 2025

Neoadjuvant PD-1/PD-L1 Inhibition Plus Chemotherapy in Borderline-Resectable or Unresectable Stage III NSCLC

In a retrospective cohort study reported in JAMA Oncology, Ricciuti et al examined whether neoadjuvant PD-1/PD-L1 inhibition plus platinum-based chemotherapy showed activity in patients with borderlin...

The ASCO Post

June 16, 2025

FDA Approves Therapy for NSCLC With High c-Met Protein Overexpression

The FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a c-Met–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, nonsquamous...

The ASCO Post

June 16, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

June 16, 2025

Extensive-Stage SCLC: Lurbinectedin and Atezolizumab

Results from the global phase III IMforte trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some p...

The ASCO Post

June 16, 2025

Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations

In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al evaluated whether afatinib prolonged progression-free survival vs platinum-base...

The ASCO Post

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant